The name change is real and well documented. On 12 May 2026 The Lancet published a global consensus health policy paper renaming the condition. The abstract states that PMOS "previously named polycystic ovary syndrome (PCOS), affects one in eight women" and that "the term PCOS is inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma." The process was led by Professor Helena Teede of Monash University alongside the AE-PCOS Society, involved 56 academic, clinical and patient organisations, drew on more than 22,000 survey responses from patients and health professionals, and ran roughly 14 years. Final agreement on the new name was reached in February 2026. The announcement was made simultaneously at the European Congress of Endocrinology in Prague. Multiple independent bodies have adopted or endorsed the term, including the Endocrine Society, the European Society of Endocrinology, the Society for Endocrinology, ASRM, Johns Hopkins Medicine, and Mayo Clinic.

Consortium leaders explicitly tie the old name to diagnostic failure. Teede is quoted saying that there is actually no increase in abnormal cysts on the ovary and that the diverse features of the condition were often unappreciated, and describes delayed diagnosis, limited awareness and inadequate care. Society materials state that reducing the disorder to a misunderstanding about cysts and a focus on ovaries "contributed to missed diagnoses and inadequate treatment."